Insider Trading Alert - SRPT, SNA And TUP Traded By Insiders
Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Crame.
Yesterday, March 3, 2015, 111 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $58.00 to $21,695,559.83.
Highlighted Stocks Traded by Insiders:
Sarepta Therapeutics (SRPT) - FREE Research Report
Christopher Nishan Garabedian, who is President and CEO at Sarepta Therapeutics, bought 800 shares at $11.81 on March 3, 2015. Following this transaction, the President and CEO owned 29,552 shares meaning that the stake was boosted by 2.78% with the 800-share transaction.
Kaye Edward M. MD, who is SVP & Chief Medical Officer at Sarepta Therapeutics, bought 800 shares at $11.81 on March 3, 2015. Following this transaction, the SVP & Chief Medical Officer owned 1,311 shares meaning that the stake was boosted by 156.56% with the 800-share transaction.
The shares most recently traded at $13.88, up $2.07, or 14.88% since the insider transaction. Historical insider transactions for Sarepta Therapeutics go as follows:
- 4-Week # shares bought: 10,000
- 4-Week # shares sold: 15,933
- 12-Week # shares bought: 10,000
- 12-Week # shares sold: 15,933
- 24-Week # shares bought: 10,000
- 24-Week # shares sold: 15,933
The average volume for Sarepta Therapeutics has been 1.0 million shares per day over the past 30 days. Sarepta Therapeutics has a market cap of $557.3 million and is part of the health care sector and drugs industry. Shares are down 7.67% year-to-date as of the close of trading on Tuesday.
Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare and infectious diseases. Currently, there are 7 analysts who rate Sarepta Therapeutics a buy, no analysts rate it a sell, and 10 rate it a hold.
Exclusive Offer: Get the latest Stock Analysis on SRPT - FREE
rates Sarepta Therapeutics as a
. The company's weaknesses can be seen in multiple areas, such as its weak operating cash flow and generally disappointing historical performance in the stock itself. Get the full
Sarepta Therapeutics Ratings Report
from
now.
Snap-on (SNA) - FREE Research Report
Fiedler John F, who is Director at Snap-on, sold 725 shares at $147.94 on March 3, 2015. Following this transaction, the Director owned 10,342 shares meaning that the stake was reduced by 6.55% with the 725-share transaction.
The shares most recently traded at $146.96, down $0.98, or 0.67% since the insider transaction. Historical insider transactions for Snap-on go as follows:
- 4-Week # shares bought: 1,000
- 4-Week # shares sold: 2,778
- 12-Week # shares bought: 1,000
- 12-Week # shares sold: 2,778
- 24-Week # shares bought: 1,000
- 24-Week # shares sold: 5,898
The average volume for Snap-on has been 333,700 shares per day over the past 30 days. Snap-on has a market cap of $8.6 billion and is part of the industrial goods sector and industrial industry. Shares are up 8.18% year-to-date as of the close of trading on Tuesday.
Snap-on Incorporated manufactures and markets tools, equipment, diagnostics, and repair information and systems solutions for professional users worldwide. The stock currently has a dividend yield of 1.43%. The company has a P/E ratio of 20.8. Currently, there are 3 analysts who rate Snap-on a buy, no analysts rate it a sell, and 1 rates it a hold.
Exclusive Offer: Get the latest Stock Analysis on SNA - FREE
rates Snap-on as a
. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, impressive record of earnings per share growth, compelling growth in net income and expanding profit margins. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full
from
now.
Tupperware Brands (TUP) - FREE Research Report
Poteshman Michael S, who is Executive Vice President & CFO at Tupperware Brands, sold 4,000 shares at $71.40 on March 3, 2015. Following this transaction, the Executive Vice President & CFO owned 17,218 shares meaning that the stake was reduced by 18.85% with the 4,000-share transaction.
The shares most recently traded at $70.79, down $0.61, or 0.86% since the insider transaction. Historical insider transactions for Tupperware Brands go as follows:
- 4-Week # shares sold: 3,086
- 12-Week # shares sold: 15,086
- 24-Week # shares sold: 46,923
The average volume for Tupperware Brands has been 597,300 shares per day over the past 30 days. Tupperware Brands has a market cap of $3.6 billion and is part of the consumer goods sector and consumer non-durables industry. Shares are up 12.87% year-to-date as of the close of trading on Tuesday.
Tupperware Brands Corporation operates as a direct-to-consumer marketer of various products across a range of brands and categories worldwide. The stock currently has a dividend yield of 3.8%. The company has a P/E ratio of 17.1. Currently, there are 2 analysts who rate Tupperware Brands a buy, 1 analyst rates it a sell, and 6 rate it a hold.
Exclusive Offer: Get the latest Stock Analysis on TUP - FREE
rates Tupperware Brands as a
. The company's strengths can be seen in multiple areas, such as its notable return on equity and expanding profit margins. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full
Tupperware Brands Ratings Report
from
now.
null